Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period from November 8, 2007, to April 30, 2008. The report details the status of various share option schemes under the UK Listing Rules, specifically providing six-monthly returns on block listings for unallotted securities.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on equity compensation plan mechanics.
| Share Option Scheme | Securities Issued/Allotted (Period) | Balance Unallotted (End of Period) |
|---|---|---|
| GlaxoSmithKline Share Option Plan - Ordinary Shares | 1,143,767 | 6,346,495 |
| GlaxoSmithKline Share Option Plan - ADS | 4,202,550 | 8,406,586 |
| GlaxoSmithKline Savings Related Share Option Scheme | 1,077,914 | 6,317,082 |
| SmithKline Beecham 1989 Executive Share Option Plan - Approved | 40,636 | 163,606 |
| Glaxo Wellcome UK Share Option Scheme | 0 | 5,119,750 |
| Glaxo Wellcome International Share Option Scheme | 0 | 13,267,156 |
| Glaxo Wellcome 1999 Share Option Plan | 0 | 1,040,000 |
| SmithKline Beecham 1989 Executive Share Option Plan - Unapproved (ADS) | 0 | 275,420 |
| SmithKline Beecham 1989 Executive Share Option Plan - Unapproved (Ordinary) | 0 | 100,000 |
| Glaxo Group Limited Share Option Scheme | 0 | 0 |
Material Changes
- Increases in Block Schemes: The "GlaxoSmithKline Share Option Plan - Ordinary Shares" increased by 5,000,000 securities. The "GlaxoSmithKline Share Option Plan - ADS" increased by 10,000,000 securities. The "GlaxoSmithKline Savings Related Share Option Scheme" increased by 5,000,000 securities.
- Issuances: Significant allotments occurred in the Ordinary Shares plan (1,143,767), ADS plan (4,202,550), Savings Related scheme (1,077,914), and the Approved Executive plan (40,636).
- No Activity: Several legacy schemes, including the Glaxo Wellcome UK and International schemes, reported zero issuances and no increases to the block listing during this period.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The document is a regulatory compliance report regarding share option inventory.
Investor Verification Checklist
- Verify the total number of shares available for future issuance across all active schemes (sum of "Balance under scheme(s) not yet issued/allotted").
- Confirm the impact of the 20,000,000 total increase in block listings on potential future dilution.
- Review the specific terms of the "GlaxoSmithKline Share Option Plan - ADS" given the high volume of issuances (4.2 million) relative to other plans.
- Check subsequent filings to determine if the zero-activity legacy schemes have been retired or remain dormant.